Somatic hypermutation signature in B-cell low-grade lymphomas

Immunoglobulin gene somatic hypermutation (SHM) is a biologically relevant and clinically useful prognostic factor in different types of low-grade B-cell lymphomas. This study of gene expression profiling identified a large number of genes that may be surrogate markers of the SHM process. Background Immunoglobulin gene somatic hypermutation is a biologically relevant and clinically useful prognostic factor in different types of low-grade B-cell lymphomas, including chronic lymphocytic leukemia, mantle cell lymphoma and splenic marginal zone lymphoma. Design and Methods With the aim of identifying surrogate markers of somatic hypermutation, a combined investigation of IgVH mutational status and expression profiles of 93 samples from patients with small B-cell lymphoma was performed. Results The analysis identified an somatic hypermutation signature of genes involved in the regulation of gene transcription, DNA repair and replication, and chromosome maintenance. Eight of these genes were subjected to protein analysis using tissue microarrays, for a set of 118 cases. We found a clear link between RAD51C and CDK7 protein expression and somatic hypermutation status, in that positive expression of either marker was significantly associated with a mutated status (p<0.003). We also found that positive expression of TFDP1 and POLA was significantly associated with ongoing somatic hypermutation (p<0.001). To assess the potential clinical applicability of these somatic hypermutation markers, we studied a series of cases of mantle cell lymphoma included in a tissue microarray. The expression of RCC1 and CDK7, separately and together, was found to be significantly associated with longer overall survival. Conclusions An somatic hypermutation signature has been identified for different types of small B-cell lymphoma. This has a potential mechanistic and diagnostic value.

[1]  N A Kolchanov,et al.  Somatic hypermutagenesis in immunoglobulin genes. II. Influence of neighbouring base sequences on mutagenesis. , 1992, Biochimica et biophysica acta.

[2]  E. Iannitto,et al.  Splenic Marginal Zone Lymphoma , 2021, Hematologic Malignancies.

[3]  M. Piris,et al.  Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation , 2007, Leukemia.

[4]  M. Ghielmini,et al.  IgVH mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome , 2005, The Journal of pathology.

[5]  S. Cajal,et al.  Immunohistochemical analysis of ZAP‐70 expression in B‐cell lymphoid neoplasms , 2005, The Journal of pathology.

[6]  E. Campo,et al.  Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. , 2003, Blood.

[7]  E. Campo,et al.  Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. , 2005, Blood.

[8]  Jaime Prilusky,et al.  GeneCards: a novel functional genomics compendium with automated data mining and query reformulation support , 1998, Bioinform..

[9]  H. Döhner,et al.  High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia , 2004, Leukemia.

[10]  A Cumano,et al.  Evolutionary and somatic selection of the antibody repertoire in the mouse. , 1987, Science.

[11]  Yupo Ma,et al.  Immunoglobulin VH somatic hypermutation in mantle cell lymphoma: mutated genotype correlates with better clinical outcome , 2006, Modern Pathology.

[12]  D. Lancet,et al.  GeneCards: integrating information about genes, proteins and diseases. , 1997, Trends in genetics : TIG.

[13]  P. Gearhart,et al.  Altered spectra of hypermutation in DNA repair-deficient mice. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[14]  Juan F. García,et al.  Variability in the Degree of Expression of Phosphorylated IκBα in Chronic Lymphocytic Leukemia Cases With Nodal Involvement , 2004, Clinical Cancer Research.

[15]  R. Tsien,et al.  Evolution of new nonantibody proteins via iterative somatic hypermutation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Nerea Martínez,et al.  The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. , 2003, Cancer research.

[17]  K. Rajewsky,et al.  Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections. , 1993, The EMBO journal.

[18]  T. Honjo,et al.  Linking class-switch recombination with somatic hypermutation , 2001, Nature Reviews Molecular Cell Biology.

[19]  A. Dopazo,et al.  Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma. , 2002, The American journal of pathology.

[20]  H. Döhner,et al.  Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  T. Golub,et al.  Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. , 2006, Cancer cell.

[22]  M. Neuberger,et al.  Somatic Hypermutation in the Absence of DNA-Dependent Protein Kinase Catalytic Subunit (DNA-Pkcs) or Recombination-Activating Gene (Rag)1 Activity , 2000, The Journal of experimental medicine.

[23]  H. Döhner,et al.  Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. , 2006, Blood.

[24]  E. Campo,et al.  Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. , 2002, Blood.

[25]  J. Benítez,et al.  Expression Profiling of T-Cell Lymphomas Differentiates Peripheral and Lymphoblastic Lymphomas and Defines Survival Related Genes , 2004, Clinical Cancer Research.

[26]  Nerea Martínez,et al.  Expression of the NF‐κB targets BCL2 and BIRC5/Survivin characterizes small B‐cell and aggressive B‐cell lymphomas, respectively , 2005, The Journal of pathology.

[27]  A. Dopazo,et al.  Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma. , 2002, The American journal of pathology.

[28]  F. Cavalli,et al.  Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22‐23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research , 2004, British journal of haematology.

[29]  H. Müller-Hermelink,et al.  Molecular analysis of human immunoglobulin heavy chain variable genes (IgVH) in normal and malignant B cells. , 1998, The American journal of pathology.

[30]  M. Piris,et al.  Transcriptional Response of T Cells to IFN-α: Changes Induced in IFN-α-Sensitive and Resistant Cutaneous T Cell Lymphoma , 2004 .

[31]  Juan F. García,et al.  Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  César Milstein,et al.  The intrinsic hypermutability of antibody heavy and light chain genes decays exponentially , 2001, The EMBO journal.

[33]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[34]  Adrian Wiestner,et al.  ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. , 2003, Blood.

[35]  Juan F. García,et al.  Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. , 2003, Blood.

[36]  L. Staudt,et al.  Signatures of the immune response. , 2001, Immunity.

[37]  L. Pasqualucci,et al.  Expression of the AID protein in normal and neoplastic B cells. , 2004, Blood.